CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 16 enrolled
Drug / intervention
GSK2256294 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03486223
NCT03486223Phase 2Completed
CompareCT.gov

Effect of Inhibition Soluble Epoxide Hydrolase on Insulin Sensitivity in Humans

Vanderbilt University Medical Center·interventional·Posted Apr 3, 2018·Updated Mar 23, 2023

In Brief

A Phase 2 clinical trial evaluating GSK2256294 and Placebo oral capsule for Diabetes Mellitus and 4 related conditions. Completed, enrolled 16 participants across 1 site.

Detailed Summary

The purpose of this study is to test how soluble epoxide hydrolase (sEH) inhibition with GSK2256294 affects tissue sEH activity and insulin sensitivity.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Endocrine System Diseases, Glucose Metabolism Disorders, PreDiabetes, Obesity
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedApr 3, 2018
Enrollment StartMay 17, 2018
Primary CompletionNov 18, 2021
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 8.2 years ago

Interventions

GSK2256294drug

Drug will be taken daily by mouth for 7 days.

Placebo oral capsuledrug

Placebo will be taken daily by mouth for 7 days.